Recombinant ACE2 was reported to be effective in slowing the progression of kidney disease by reducing albumin excretion and modulating RAS depressor arm (AT2R, ACE2, Ang 1–7) by ACE2 activator or AT2R agonist might protect the kidney from renal injury (Oudit et al., 2010; Sharma, Malek, Mulay, & Gaikwad, 2019), which may provide potential clues for clinicians encountering COVID‐19 patients, especially complicated with kidney injury. The gene discussed is ANGPT1; the disease is COVID-19.